Galectin Therapeutics Inc. (GALT)

[biotech2010]

There is supposed to be a correlation between Alpha2 Macroglobulin and liver stiffnesss but neither of the tests used in the FX trial measured this biomarker and there is no established correlation for all of this.

Basically, they were doing a short term investigation that, according to Traber, 'might have yielded something important' but there was no guarantee.

To represent the FX trial as anything more than a shot in the dark was irresponsible on the part of Traber and GALT but it's too late for concern or even for discussion. I sold 60% of my long term GALT shares after the results were announced and had sold a similar amount of trading shares prior to the announcement (at a solid profit), I wish I had sold all of it before the announcement but am far too invested emotionally in the company to have done so.